Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flesinoxan
- Development stage
- Discontinued
- Lead developer
- Duphar
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flesinoxan is a small molecule, potent, and highly selective 5-HT1A receptor full agonist belonging to the phenylpiperazine class. Originally developed by Duphar (later Solvay Pharmaceuticals) as an antihypertensive agent, its development shifted toward psychiatric indications after animal models demonstrated significant antidepressant and anxiolytic-like effects. In human clinical trials, flesinoxan was evaluated for the treatment of major depressive disorder (MDD) and various anxiety disorders. Despite showing efficacy and a favorable safety profile in pilot studies, its clinical development was discontinued by the sponsor for strategic management reasons rather than safety or efficacy failures.
- Other names
- flesinoxan hydrochloride
02
Targets
DRD2 (Dopamine D2 Receptor)5-HT2 (5-HT2 receptor family)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on flesinoxan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flesinoxan.